rn0191
Small moleculeexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jul 14, 2023 (NCT05905068)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Subtilisin/kexin type 9INHIBITOR
PCSK9 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06132360 | Phase 1 | Feb 29, 2024 | Government of China, Ikaria |
| NCT05905068 | Phase 1 | Jul 14, 2023 | Ikaria, Nucleus Network Ltd |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Ikaria | For profit | 2 | 2 | 1 | 2023 |
| Government of China | Government | 1 | 1 | 1 | 2024 |
| Nucleus Network Ltd | For profit | 1 | 0 | 1 | 2023 |
3 organizations
Page 1 / 1